Loading
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Latest quote
$36.90
+$0.90 · +2.50%
Regular session · ET · Market data may be delayed.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Day range
Current $36.90
52-week range
Current $36.90
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
61
Bullish
Risk
55
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Day range
Current $36.90
52-week range
Current $36.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 45.95M USD | 1.08M USD | 151K USD |
| Gross profit | 45.95M USD | 1.08M USD | 151K USD |
| Research and development | 97.58M USD | 65.34M USD | 35.98M USD |
| Selling, general, and administrative | 29.16M USD | 16.56M USD | 9.72M USD |
| Operating expenses | 126.75M USD | 81.9M USD | −1.92M USD |
| Interest income | 19.53M USD | 8.62M USD | 2.79M USD |
| Depreciation and amortization | 1.6M USD | 1.4M USD | 848K USD |
| Operating income | −80.8M USD | −80.82M USD | 2.08M USD |
| Net income | −48.88M USD | −71.8M USD | 4.18M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI35.39M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM20.98M0.03%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF10.17M0.01%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P Pharmaceuticals ETFXPH8.42M1.82%462.1M USD0.35%$63.63+1.14%
iShares Biotechnology ETFIBB7.95M0.08%10.4B USD0.44%$200.48-1.41%
First Trust Small Cap Growth AlphaDEX FundFYC7.87M0.59%1.36B USD0.70%$113.82-0.39%
iShares Russell 2000 Growth ETFIWO4.91M0.04%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO4.85M0.03%18B USD0.06%$112.1-0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
